tert-butyl (4R)-4-(benzyloxycarbonylamino)-4-carbamoylbutyrate | 77340-94-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl (4R)-4-(benzyloxycarbonylamino)-4-carbamoylbutyrate
• 英文别名: tert-butyl (4R)-5-amino-5-oxo-4-(phenylmethoxycarbonylamino)pentanoate
• CAS: 77340-94-4
• 化学式: C₁₇H₂₄N₂O₅
• 分子量: 336.388
• InChiKey: FVASJFMQBNYNSN-CYBMUJFWSA-N

物化性质

• 熔点：
  138-140 °C
• 沸点：
  544.6±50.0 °C(Predicted)
• 密度：
  1.168±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  24
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  108
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl (4R)-4-(benzyloxycarbonylamino)-4-carbamoylbutyrate 在 Pd-C ammonium chloride 、 三氯氧磷 作用下， 以 吡啶 、 乙醇 、 正己烷 、 二氯甲烷 、 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 生成 tert-butyl (4R)-4-amino-4-(5-tetrazolyl)butyrate
  参考文献：
  名称：

  Anti-cancer compounds

  摘要：

  公式（I）的环戊喹唑啉：其中R.sup.1是氢，氨基，C.sub.1-4烷基，C.sub.1-4烷氧基，C.sub.1-4羟基烷基或C.sub.1-4氟烷基；其中R.sup.2是氢，C.sub.1-4烷基，C.sub.3-4烯基，C.sub.3-4炔基，C.sub.2-4羟基烷基，C.sub.2-4卤代烷基或C.sub.1-4氰基烷基；Ar.sup.1是苯基，噻吩二基，噻唑二基，吡啶二基或嘧啶二基，可以选择性地带有一个或两个取代基，所述取代基选自卤素，羟基，氨基，硝基，氰基，三氟甲基，C.sub.1-4烷基和C.sub.1-4烷氧基；其中R.sup.3是以下式的基团：--A.sup.1--Ar.sup.2--A.sup.2--Y.sup.1，其中A.sup.1，A.sub.2，Y.sup.1和Ar.sub.2如权利要求1中定义；或其药学上可接受的盐或酯在治疗癌症方面具有治疗价值。

  公开号：

  US05747499A1
• 作为产物：
  描述：

  Z-D-叔丁基谷氨酸 在 ammonium hydroxide 、 N-羟基丁二酰亚胺 、 N,N'-二环己基碳二亚胺 作用下， 生成 tert-butyl (4R)-4-(benzyloxycarbonylamino)-4-carbamoylbutyrate
  参考文献：
  名称：

  Synthesis, and the Adjuvant and Tumor-Suppressive Activities of Quinonyl Muramyl Dipeptides

  摘要：

  ω-(1,4-苯醌-2-基)烷酸、2-[10-(5,6-二甲氧基-3-甲基-1,4-苯并苯醌-2-基)癸基]-3-羟基二十四面酸、全反式-5,9,13,17-四甲基-4,8,12,16-十八碳四烯酸和硬脂酸被偶联到脂质双肽 muramyl dipeptide 的糖部分6-O位置上，形成了6-O-酰氨基muramyl dipeptide甲酯。所使用的酰氨基残基为甘氨酸、亮氨酸、己二酸和叔丁基胺。开发了新的合成方法来制备ω-(1,4-苯醌-2-基)烷酸，如22-(5,6-二甲氧基-3-甲基-1,4-苯醌-2-基)二十二酸，以及α-分支的ω-(1,4-苯醌-2-基)β-羟基酸，即2-[10-(5,6-二甲氧基-3-甲基-1,4-苯醌-2-基)癸基]-3-羟基二十四酸。测定了这些醌基、多烯丙基乙酰基和硬脂酰基muramyl dipeptide在诱导豚鼠对ABA-酪氨酸迟发型超敏反应和抑制同系BALB/c雌性小鼠肿瘤(meth-A)活性中的作用。结果表明，所有这些muramyl dipeptide衍生物都保留了佐剂活性，而只有醌基muramyl dipeptides显示出较强的肿瘤抑制活性，表明5,6-二甲氧基-3-甲基-1,4-苯醌环对于显现肿瘤抑制活性是必需的。分子的亲脂性-亲水性平衡也很重要。在所测试的化合物中，N-乙酰基-6-O-[10-(5,6-二甲氧基-3-甲基-1,4-苯醌-2-基)癸酰基]muramyl-l-缬氨酸-d-异谷氨酰胺甲酯显示出最强的肿瘤抑制活性。该化合物在豚鼠中也显示出肿瘤退缩活性，因此是一个有前景的研究候选物。

  DOI：

  10.1246/bcsj.57.3182

文献信息

• Synthesis and reactions of O-acetylated benzyl α-glycosides of 6-O-(2-acetamido-2-deoxy-β-d-glucopyranosyl)-N-acetylmuramoyl-l-alanyl-d-isoglutamine esters: the base-catalysed isoglutamine ⇄ glutamine rearrangement in peptidoglycan-related structures
  作者：Dina Keglević、Andrew E. Derome

  DOI：10.1016/0008-6215(89)84005-4

  日期：1989.2

  Abstract Condensation of benzyl 2-acetamido-6- O -(2-acetamido-3,4,6-tri- O -acetyl-2-deoxy-3- O -[( R -1-carboxyethyl]-α- d -glucopyranoside ( 2 ) and its 4-acetate ( 4 ) with l -alanyl- d -isoglutamine benzyl ester via the mixed anhydride method yielded N -[2- O -[benzyl 2-acetamido-6- O -(2-acetamido-3,4,6-tri- O -acetyl-2-deoxy-β- d -glucopyranosyl)-2,3-dideoxy-α- d -glucopyranosid-3-yl]-( R )-

  5和6的O脱乙酰基化导致异谷氨酰胺残基的酯交换和α→γ酰胺化，得到N-[2- O-[苄基2-乙酰氨基-6- O-（2-乙酰氨基-2-脱氧-β- d-吡喃葡萄糖基）-2，3-二脱氧-α-d-吡喃葡萄糖苷-3-基]-（R）-乳酰基] -1-丙氨酰基-d-异谷氨酰胺甲酯（8）和​​-谷氨酰胺甲酯（9）。用MgO-甲醇处理6，在GlcNAc残基处引起脱乙酰基作用，得到N-[2- O-[苄基2-乙酰氨基-6-O-（2-乙酰氨基-2-脱氧-β-d-葡萄糖吡喃糖基）的混合物-4- O-乙酰基-2,3-二脱氧-α-d-吡喃葡萄糖苷-3-基]-（R）-乳酰基] -1-丙氨酰-d-异谷氨酰胺甲酯（11）和-谷氨酰胺甲酯（12 ）。肽聚糖相关结构的苄基或甲基酯保护与任何需要碱性介质的反应都不兼容。
• Synthesis of Fluoro-containing muramyl dipeptide analogs
  作者：Zheng-Fu Wang、Jie-Cheng Xu

  DOI：10.1016/s0040-4020(98)00738-8

  日期：1998.10

  Twelve Fluoro-containing muramyl dipeptide analogs with perfluoroalkyl at C1 of sugar moiety or C-terminal of peptidyl chain were synthesized.

  合成了十二个在糖基的C1或肽基链的C端具有全氟烷基的含氟的对甲基二肽类似物。
• Glucosamine peptide derivatives, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04369178A1

  公开（公告）日：1983-01-18

  Novel glucosamine-peptide derivatives of the formula: ##STR1## wherein m is 0 or 1; n is 0 or an integer of 1 to 9; R is lower alkyl which may be substituted with hydroxyl, or aryl; R.sup.1 is hydrogen or acyl having an acyclic hydrocarbon group, the terminal of which may be substituted with a cyclic hydrocarbon group directly, via a carbonyl group or via an oxygen atom; provided that when R.sup.1 is hydrogen m is 1; R.sup.2 is hydrogen or lower alkyl which may form a ring by connecting its terminal with the .alpha.-nitrogen atom when n is 0, or hydrogen when n is an integer of 1 to 9; R.sup.3 is hydrogen or lower alkyl; R.sup.4 and R.sup.5 are each hydrogen or lower alkyl which may be substituted with hydroxyl or benzyloxyl; R.sup.6 is hydrogen or lower alkyl; R.sup.7 is alkyl which may be substituted with lower alkoxyl or aralkyl; R.sup.8 and R.sup.9 are each hydrogen, lower alkyl or aralkyl; and (D) and (L) each indicate configurations if their respective carbon atoms are asymmetric; or an acid addition salt thereof, have immunostimulatory activity.

  新型葡萄糖胺-肽衍生物的化学式如下：##STR1## 其中m为0或1；n为0或1至9的整数；R为可以用羟基取代的低碳烷基，或芳基；R.sup.1为氢或酰基，具有一个线性碳氢基团，其末端可以直接或通过羰基或氧原子与一个环烃基团相连；当R.sup.1为氢时，m为1；R.sup.2为氢或可以通过将其末端与α-氮原子连接而形成环的低碳烷基，或当n为1至9的整数时为氢；R.sup.3为氢或低碳烷基；R.sup.4和R.sup.5分别为氢或可以用羟基或苄氧基取代的低碳烷基；R.sup.6为氢或低碳烷基；R.sup.7为可以用低碳烷氧基或芳基取代的烷基；R.sup.8和R.sup.9分别为氢、低碳烷基或芳基；(D)和(L)分别表示它们各自的碳原子具有对映异构体；或其酸盐加合物具有免疫刺激活性。
• Synthesis of Muramyl Peptides Containing meso-Diaminopimelic Acid
  作者：Niels Kubasch、Richard R. Schmidt

  DOI：10.1002/1099-0690(200208)2002:16<2710::aid-ejoc2710>3.0.co;2-8

  日期：2002.8

  Chain-extension Of L-glutamate aldehyde 3 by means of the Wittig-Homer reaction furnished the desired C-7 dicarboxylic acid derivative, which in turn, after C-C double bond hydrogenation and protecting group manipulation, afforded the 2,6-diaminopimelic acid derivatives (S,R)-9 and (S,S)-9, both with the desired orthogonal protecting group pattern. Synthesis of the muramic acid derivative 15 and attachment of an L-alanine residue furnished muramyl-L-alanine 18. The corresponding 1,6-anhydromuramic acid derivative 26 was obtained similarly. Treatment of these compounds with peptides 28-30 and with the 2,6-diaminopimelic acid containing di- and tripeptides 32a, 32b, and 35 gave the protected muramyl peptides 17, 37, 40, 42, 44, 46, and 49a and 49b, which, after deprotection, afforded the desired target molecules muramyl-L-alanine (38), muramyl-L-alanyl-D-glutamic acid (39), muramyl-L-alanyl-D-glutaminide (41), muramyl-L-alanyl-D-isoglutaminyl-L-lysine (43), muramyl-L-alanyl-D-isoglutaminyl-(2S,6R)-2,6-diaminopimelic acid (45), muramyl-L-alanylL-isoglutaminyl-(2S,6R)-2,6-dian-Anopimelinyl-D-alanine (47), 1,6-anhydromuramyl-L-alanyl-D-isoglutaminyl-(2S,6R)-2,6-diaminopimelic acid (50a), and 1,6-anhydromuramyl-L-alanyl-Disoglutaminyl-(2S,6S)-2,6-diaminiopimelic acid (50b). (C) Wiley-VCH Verlag GmbH, 69451 Weinheim, Germany, 2002.
• Design and Synthesis of Cyclopenta[<i>g</i>]quinazoline-Based Antifolates as Inhibitors of Thymidylate Synthase and Potential Antitumor Agents^,
  作者：Vassilios Bavetsias、Jonathan H. Marriott、Camille Melin、Rosemary Kimbell、Zbigniew S. Matusiak、F. Thomas Boyle、Ann L. Jackman

  DOI：10.1021/jm991119p

  日期：2000.5.1

  Following the development of raltitrexed, the synthesis of nonpolyglutamatable inhibitors of TS that do not use the reduced folate carrier (RFC) for cellular entry should provide compounds which overcome mechanisms of resistance to folate-based inhibitors of TS that are associated with decreased/altered folylpolyglutamate synthetase (FPGS) expression and/or an impaired RFC. Examination of a computer graphics model of the humanized Escherichia coli TS enzyme with quinazoline inhibitors of TS, such as 1 bound in the active site of the enzyme, suggested that conformational restriction introduced by bridging the C9 with C7 to form a pentacycle may be beneficial for binding to TS. That led to the synthesis of a series of potent cyclopenta[g]quinazoline-based inhibitors of the enzyme in which the glutamyl residue associated with classical antifolates was replaced with a variety of glutamate-derived ligands; the most potent inhibitor being the L-Glu-gamma-D-GluT(alpha) derivative 7j. In the mouse L1210:1565 cell line (mutant RFC), the majority of these compounds had activity equal or only slightly greater compared with the parental L1210 cell line, indicating a reduced dependence on the RFC for cellular uptake in the L1210 cell line.